Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OAT ICI in Solid Tumors
NCT07661459Phase 2Recruiting
- Sponsor
- Val Adams
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of aspirin and loratadine in solid tumor (2 arms), sponsored by Val Adams. Primary endpoint: 18-Week Response Rate. Started Jun 2026; status: recruiting.
02
Drugs
aspirinloratadine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07661459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07661459.